Bronzert D A, Triche T J, Gleason P, Lippman M E
Cancer Res. 1984 Sep;44(9):3942-51.
The mechanism by which pharmacological concentrations of estrogen can paradoxically inhibit the growth of human breast cancer is unknown. We have selected for a variant line of MCF-7 which may help to understand this process. The variant was selected by exposing MCF-7 cells to high-specific-activity 16 alpha-[125I]iodoestradiol. These cells were viably frozen for two isotopic half-lives, defrosted once, then reexposed to 16 alpha-[125I]iodoestradiol to allow maximal radiation damage mediated by isotope associated with binding sites. This cell line (113) is one of 55 lines cloned from MCF-7 cells that survived this treatment. The growth response to estradiol of the 113 breast cancer cells grown in monolayer is normal for 4 to 6 days, and then the cell number plateaus as the cells appear to round up and detach. Concomitantly, a decrease in [3H]thymidine incorporation occurs. The cells cannot be rescued by removing estradiol from the medium. The inhibition is dose dependent and can be seen in concentrations of estradiol as low as 10(-10) M. The 113 cells are also inhibited by antiestrogens. They have normal levels of estrogen receptors which bind to DNA cellulose with activation. Progesterone receptors are estrogen inducible, although the levels are one-third that of wild-type MCF-7 cells. The morphological changes determined by electron microscopy of estrogen-treated cells are typical of degenerative cells. To investigate the possibility that inhibitory factors are secreted into the medium by 113 cells, conditioned medium from estrogen-exposed 113 cells is added to normal MCF-7 and 113 cells. No decrease in [3H]thymidine incorporation compared to controls is observed. When the secreted proteins are labeled with [35S]methionine and analyzed by sodium dodecyl sulfate-acrylamide gels, no major differences are apparent in the 113 and MCF-7 cells. Thus, the source of the defect is still unknown. It remains to be seen if the growth-inhibitory effects of 17 beta-estradiol on this cell line are receptor mediated or related to specific gene products which can be identified.
药理浓度的雌激素反而能抑制人类乳腺癌生长的机制尚不清楚。我们筛选出了一株MCF - 7变异细胞系,这可能有助于理解这一过程。该变异细胞系是通过将MCF - 7细胞暴露于高比活度的16α-[125I]碘雌二醇而筛选出来的。这些细胞被液氮冻存两个同位素半衰期,解冻一次,然后再次暴露于16α-[125I]碘雌二醇,以使与结合位点相关的同位素介导最大程度的辐射损伤。这个细胞系(113)是从经此处理后存活的MCF - 7细胞中克隆出的55个细胞系之一。单层培养的113乳腺癌细胞对雌二醇的生长反应在4至6天内是正常的,然后细胞数量趋于平稳,因为细胞似乎变圆并脱离。与此同时,[3H]胸腺嘧啶核苷掺入量减少。从培养基中去除雌二醇并不能挽救这些细胞。这种抑制作用是剂量依赖性的,在低至10(-10) M的雌二醇浓度下就能观察到。113细胞也受到抗雌激素的抑制。它们具有正常水平的雌激素受体,该受体能与DNA纤维素结合并被激活。孕激素受体是雌激素诱导型的,尽管其水平是野生型MCF - 7细胞的三分之一。通过电子显微镜观察,经雌激素处理的细胞的形态变化是退化细胞的典型特征。为了研究113细胞是否向培养基中分泌抑制因子,将来自经雌激素处理的113细胞的条件培养基添加到正常MCF - 7细胞和113细胞中。与对照组相比,未观察到[3H]胸腺嘧啶核苷掺入量减少。当用[35S]甲硫氨酸标记分泌蛋白并通过十二烷基硫酸钠 - 丙烯酰胺凝胶分析时,113细胞和MCF - 7细胞之间没有明显的主要差异。因此,缺陷的来源仍然未知。17β - 雌二醇对该细胞系的生长抑制作用是否由受体介导或与可识别的特定基因产物有关,仍有待观察。